An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Simulations Plus, Inc. (NASDAQ: SLP) announced that CEO Shawn O’Connor will present at the Sidoti Winter Small Cap Investor Conference on January 19–20, 2022. O’Connor's presentation is scheduled for January 19, 2022, at 4:00 p.m. ET. Investors can access a live webcast through the Sidoti website. Simulations Plus, a leader in biosimulation, supports drug discovery and development across the globe.
Positive
None.
Negative
None.
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Winter Small Cap Investor Conference taking place virtually on January 19–20, 2022.
Mr. O’Connor will be presenting on January 19, 2022, at 4:00 p.m. ET, and he will be meeting with investors throughout both days of the virtual investor conference. A live webcast of the Company’s presentation will be available through the Sidoti website. For more information about the conference or to schedule a meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com.
About Simulations Plus
Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.
